GIP and obesity due to melanocortin 4 receptor deficiency: Of note, in the SURMOUNT-1 phase III trial performed in adults with obesity, once-weekly tirzepatide, a dual agonist of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), demonstrated substantial reductions in body weight of up to 22.5%, with greater improvements than placebo in cardiometabolic risk factors, including waist circumference, systolic and diastolic blood pressure, and fasting insulin, lipid, and aspartate aminotransferase levels (62).